290 related articles for article (PubMed ID: 36453516)
1. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.
Saygin C; Cannova J; Stock W; Muffly L
Haematologica; 2022 Dec; 107(12):2783-2793. PubMed ID: 36453516
[TBL] [Abstract][Full Text] [Related]
2. MRD in ALL: Optimization and Innovations.
Pierce E; Mautner B; Mort J; Blewett A; Morris A; Keng M; El Chaer F
Curr Hematol Malig Rep; 2022 Aug; 17(4):69-81. PubMed ID: 35616771
[TBL] [Abstract][Full Text] [Related]
3. Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?
Logan AC
Best Pract Res Clin Haematol; 2022 Dec; 35(4):101407. PubMed ID: 36517126
[TBL] [Abstract][Full Text] [Related]
4. Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study.
Ashouri K; Nittur V; Ginosyan AA; Hwang J; Adnani B; Chen D; Savitala-Damerla L; Schiff K; Chaudhary P; Kovach AE; Ladha A; Siddiqi I; Ali A; Woan K; Tam E; Yaghmour G
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e59-e66.e2. PubMed ID: 38061959
[TBL] [Abstract][Full Text] [Related]
5. Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia.
Ramos Elbal E; Fuster JL; Campillo JA; Galera AM; Cortés MB; Llinares ME; Jiménez I; Plaza M; Martínez Banaclocha H; Galián JA; Blanquer Blanquer M; Martínez Sánchez MV; Muro M; Minguela A
Clin Transl Oncol; 2024 Jan; 26(1):278-287. PubMed ID: 37368200
[TBL] [Abstract][Full Text] [Related]
6. Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.
Short NJ; Jabbour E
Curr Oncol Rep; 2017 Jan; 19(1):6. PubMed ID: 28205134
[TBL] [Abstract][Full Text] [Related]
7. Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene.
Sun YQ; Li SQ; Zhao XS; Chang YJ
Expert Rev Anticancer Ther; 2020 Jun; 20(6):453-464. PubMed ID: 32459519
[TBL] [Abstract][Full Text] [Related]
8. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B-cell acute lymphoblastic leukemia patients detected by next-generation sequencing.
Gu M; Xia Y; Zhang J; Tang Y; Xu W; Song H; Xu X
Cancer Med; 2023 Dec; 12(24):21978-21984. PubMed ID: 38063317
[TBL] [Abstract][Full Text] [Related]
10. Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia.
Kruse A; Abdel-Azim N; Kim HN; Ruan Y; Phan V; Ogana H; Wang W; Lee R; Gang EJ; Khazal S; Kim YM
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033444
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
12. Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia.
Hein K; Short N; Jabbour E; Yilmaz M
Blood Lymphat Cancer; 2022; 12():7-16. PubMed ID: 35340663
[TBL] [Abstract][Full Text] [Related]
13. Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment.
Hu G; Cheng Y; Zuo Y; Chang Y; Suo P; Jia Y; Lu A; Wang Y; Jiao S; Zhang L; Sun Y; Yan C; Xu L; Zhang X; Liu K; Wang Y; Zhang L; Huang X
Front Immunol; 2022; 13():915590. PubMed ID: 35734165
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
Logan AC; Vashi N; Faham M; Carlton V; Kong K; Buño I; Zheng J; Moorhead M; Klinger M; Zhang B; Waqar A; Zehnder JL; Miklos DB
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1307-13. PubMed ID: 24769317
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy.
Yurkiewicz I; Craig J; Muffly L
Curr Hematol Malig Rep; 2020 Jun; 15(3):187-193. PubMed ID: 32358681
[TBL] [Abstract][Full Text] [Related]
16. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
[TBL] [Abstract][Full Text] [Related]
17. Correlation between a 10-color flow cytometric measurable residual disease (MRD) analysis and molecular MRD in adult B-acute lymphoblastic leukemia.
Singh J; Gorniak M; Grigoriadis G; Westerman D; McBean M; Venn N; Law T; Sutton R; Morgan S; Fleming S
Cytometry B Clin Cytom; 2022 Mar; 102(2):115-122. PubMed ID: 34806309
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
19. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]